Some literature data say that it is BDNF that influences the expression of miRNA-134 by activating the TrkB pathway [17], which would confirm our results, where, with low levels of BDNF expression, we observed a reduction levels of miR-134 from MS patients. The gene discussed is NTRK2; the disease is myeloid sarcoma.